Status:
UNKNOWN
Comparison of Bronchodilator Treatment Practices in Group E COPD Patients
Lead Sponsor:
Ataturk University
Conditions:
COPD Exacerbation Acute
Eligibility:
All Genders
40-75 years
Phase:
NA
Brief Summary
COPD is a heterogeneous condition caused by airway (bronchitis/bronchiolitis) or alveolar (emphysema) abnormality, changes with chronic respiratory changes (dyspnea, dyspnoea, phlegm). It is character...
Eligibility Criteria
Inclusion
- Group E COPD patients
Exclusion
- Recent MI
- Pulmonary embolism
- Cerebral aneurysm
- Active hemoptysis
- Pneumothorax
- Nausea, vomiting
- Recent thorax, abdominal, and eye surgery were identified in the patients before the pulmonary function test and were not included in the study.
- Mental retardation
- Pneumonia with acute exacerbation of COPD
- Patients with pulmonary edema due to congestive heart failure
- Patients with interstitial lung disease along with COPD
Key Trial Info
Start Date :
January 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2025
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT06178068
Start Date
January 1 2024
End Date
January 1 2025
Last Update
December 20 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.